Michael D. Dalzell/Editing Samples



Rapid advances in the treatment of cancer have led to an explosion of targeted therapies. The relatively small evidence base to describe long-term outcomes, however, has left managed care organizations, employers, and government payers uncertain about how to evaluate these products. I led a team of editors that worked with Genentech to produce this clinical brief, which was intended to help third-party payers and others gain a deeper understanding of the roles and relevance of surrogate clinical trial endpoints.